The Library

Insulin mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by Rosiglitazone

Tools

Harte, A. L. (Alison L.), McTernan, P. G. (Philip G.), Chetty, Rajkumar, Coppack, Simon, Katz, Jonathan, Smith, Stephen and Kumar, Sudhesh. (2005) Insulin mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by Rosiglitazone. Circulation, Vol.111 . pp. 1654-1961. ISSN 0009-7322

[img]
Preview
 PDF
WRAP_Kumar_2005_-_Post-print_version_-_Insulin_mediated_upregulation.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (223Kb)

Abstract

Background: Obesity associated hypertension is likely to be due to multiple mechanisms. Identification of the renin-angiotensin system (RAS) within adipose tissue does, however, suggest a potential causal role for it in obesity-associated hypertension. Obese patients are often hyperinsulinaemic, but mechanisms underlying insulin upregulation of the RAS in adipose tissue are unclear. TNFα, an inducer of angiotensinogen in hepatocytes, is elevated in hyperinsulinaemic, obese individuals, and may provide a link in mediating insulin upregulation of the RAS in adipose tissue. Further, thiazolidinediones lower blood pressure in vivo and downregulation of the RAS in adipose tissue may contribute to this effect. We therefore examined the effect of rosiglitazone (RSG), on the insulin mediated upregulation of the RAS.
Methods and Results: Sera were obtained from the arterial circulation and from venous blood draining subcutaneous abdominal adipose tissue. Isolated human abdominal subcutaneous adipocytes (n=12) were treated with insulin (1-1000nM) and insulin in combination with RSG (10nM), and RSG (10nM) alone to determine angiotensinogen expression, angiotensin II, bradykinin and TNFα secretion. Subcutaneous adipocytes were also treated with TNFα (10-100ng/mL) to examine the direct effect on angiotensinogen expression and angiotensin II secretion. The findings showed that the arterio-venous difference in angiotensin II levels was significant (↑23%; p<0.001). Insulin increased TNFα secretion in a concentration-dependent manner (p<0.01) whilst RSG (10nM) significantly reduced the insulin mediated rise in TNFα (p<0.001), as well as AGT and angiotensin II. TNFα also increased angiotensinogen and angiotensin II in isolated adipocytes.
Conclusions: Our in vivo data suggest that human subcutaneous adipose tissue is a significant source of angiotensin II. This study also demonstrates a potential TNFα mediated
mechanism through which insulin may stimulate the RAS and may contribute to explain obesity associated hypertension. RSG downregulates the RAS in subcutaneous adipose tissue and this effect may contribute to the long-term effect of RSG on blood pressure.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI)
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Obesity, Hypertension, Angiotensin II, Adipose tissues
Journal or Publication Title: Circulation
Publisher: American Heart Association
ISSN: 0009-7322
Official Date: 2005
Volume: Vol.111
Page Range: pp. 1654-1961
Identification Number: 10.1161/01.CIR.0000161954.17870.5D
Status: Peer Reviewed
Access rights to Published version: Open Access
Description: Version accepted by publisher (post-print, after peer review, before copy-editing).
References:

1. Must A, Spandano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9.
2. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to Angiotensin II. J Clin Endocrinol Metab 1998; 83: 3925-3929.
3. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58 (1): 460-461.
4. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969-73.
5. Intengan HD, Shiffrin EL. Vascular remodelling in hypertension: roles of apoptosis, inflammation and fibrosis. Hypertension 2001; 38 (pt 2): 581-587.
6. Linz W, Wiemer G, Schlkens BA. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol 1997; 80: 118A-1123A.
7. Harte AL, McTernan PG, McTernan CL, Crocker J, Starcynski J, Barnett AH, Matyka K, Kumar S. Insulin increases angiotensinogen expression in human abdominal subcutaneous adipocytes. Diabetes Obes Metab. 2003 Nov 5 (6):462-7.
8. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose Expression of Tumour Necrosis Factor-alpha: Direct Role in Obesity-Linked Insulin Resistance. Science 1993; 259: 87-90.
9. Winkler G, Salamon F, Salamon DGS, Simon K, Cseh K. Elevated serum tumour necrosis factor-alpha levels can contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and in obesity. Diabetologia 1998; 41: 860-861.
10. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumour necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2003; 27 (1): 88-94.
11. Brasier AR & Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 1996; 27: 465-475.
12. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
13. Bakris GL, Dole JF, Porter LE, Huang C, Freed M. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000; 49 (Suppl 1): A96.
19
14. Bennett SMA, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, Wilding JPH. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetic Medicine 2004; 21: 415-422.
15. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064.
16. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
17. Frayn KN, Coppack SW, Humphries SM, Whyte PL. Metabolic characteristics of human adipose tissue in vivo. Clin. Sci (Colch) 1989; 76: 509-516.
18. Klein S, Coppack SW, Mohamed-Ali V, Landt M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes 1996; 45: 984-987.
19. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999; 277 (6 Pt 1):E971-5.
20. Rodbell M. Metabolism of isolated adipocytes. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964; 239: 375-380.
21. Anwar A, McTernan PG, Anderson LA, Askaa J, Moody CG, Barnett AH, Eggo MC, Kumar S. Expression and Regulation of Oestrogen Receptor alpha and beta in human adipose tissue. Diabetes, Obesity & Metabolism 2001; 3: 338-349.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Analytical Biochem 1976; 72: 807-811.
23. McTernan PG, Sheppard MC, Williams GR. Hormone-induced changes in nuclear receptor stoichiometry in HL60 cells correlate with induction of monocyte or neutrophil differentiation. J Endocrinol 1998; 156:135-148.
24. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE.Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension. 1996; 28 (6):1047-54.
25. Faloia E, Gatti C, Camilloni MA, Mariniello B, Sardu C, Garrapa GG, Mantero F, Giacchetti G. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest. 2002; 25 (4):309-14.
26. Schofield I, Malik R, Izzard A, Austin C, Heagerty A.Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation. 2002; 106(24):3037-43.
27. Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozakova M, La Canna G, Nardi M, Guelfi D, Salvetti M, Morizzo C, Vittone F, Rosei EA. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. .J Hypertension 2003; 21 (3):625-31.
28. Taubman MB, Berk BC, Izumo S, Tsuda T, Alexander RW, Nadal-Ginard B. Angiotensin II induces c-fos mRNA in aortic smooth muscle. Role of Ca2+ mobilization and protein kinase C activation. J Biol Chem. 1989; 5;264(1):526-30.
29. Luft FC. Workshop: Mechanisms and cardiovascular damage in hypertension. Hypertension 2001; 37 (2 Part 2): 594-598.
30. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15 (14)272-9.
31. Da Ros R, Assaloni R, Ceriello A. The preventative anti-oxidant action of thiazolidinediones: a therapeutic prospect in diabetes and insulin resistance. Diab Med. 2004; 21(11): 1249-52.
URI: http://wrap.warwick.ac.uk/id/eprint/167

Request changes to a record

Actions (login required)

View Item View Item

Document Downloads

More statistics for this item...